Miracle Mile Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.43M | Sell |
111,561
-257
| -0.2% | -$14.8K | 0.08% | 181 |
|
|
2026
Q1 | $6.78M | Sell |
111,818
-60
| -0.1% | -$3.5K | 0.09% | 156 |
|
|
2025
Q4 | $6.03M | Buy |
111,878
+513
| +0.5% | +$24.7K | 0.09% | 166 |
|
|
2025
Q3 | $5.02M | Sell |
111,365
-1,955
| -2% | -$91.3K | 0.08% | 182 |
|
|
2025
Q2 | $5.25M | Buy |
113,320
+799
| +0.7% | +$39.2K | 0.09% | 150 |
|
|
2025
Q1 | $6.86M | Sell |
112,521
-1,524
| -1% | -$88.8K | 0.14% | 107 |
|
|
2024
Q4 | $6.45M | Buy |
114,045
+7,109
| +7% | +$397K | 0.13% | 114 |
|
|
2024
Q3 | $5.53M | Sell |
106,936
-613
| -0.6% | -$28.8K | 0.13% | 106 |
|
|
2024
Q2 | $4.47M | Buy |
107,549
+10,749
| +11% | +$481K | 0.11% | 117 |
|
|
2024
Q1 | $5.25M | Buy |
96,800
+89,568
| +1,238% | +$4.56M | 0.13% | 109 |
|
|
2023
Q4 | $371K | Sell |
7,232
-846
| -10% | -$44.4K | 0.01% | 368 |
|
|
2023
Q3 | $469K | Sell |
8,078
-299
| -4% | -$18.3K | 0.01% | 333 |
|
|
2023
Q2 | $536K | Buy |
8,377
+799
| +11% | +$53.6K | 0.02% | 340 |
|
|
2023
Q1 | $525K | Sell |
7,578
-796
| -10% | -$56.1K | 0.02% | 351 |
|
|
2022
Q4 | $602K | Sell |
8,374
-1,968
| -19% | -$148K | 0.02% | 328 |
|
|
2022
Q3 | $735K | Sell |
10,342
-9,503
| -48% | -$689K | 0.03% | 239 |
|
|
2022
Q2 | $1.53M | Buy |
19,845
+6,359
| +47% | +$484K | 0.07% | 174 |
|
|
2022
Q1 | $985K | Buy |
13,486
+9,081
| +206% | +$610K | 0.04% | 237 |
|
|
2021
Q4 | $275K | Sell |
4,405
-209
| -5% | -$12.3K | 0.01% | 384 |
|
|
2021
Q3 | $273K | Buy |
4,614
+628
| +16% | +$41.4K | 0.01% | 371 |
|
|
2021
Q2 | $266K | Buy |
3,986
+373
| +10% | +$24.3K | 0.01% | 329 |
|
|
2021
Q1 | $228K | Sell |
3,613
-1,533
| -30% | -$95.4K | 0.01% | 344 |
|
|
2020
Q4 | $319K | Sell |
5,146
-280
| -5% | -$17.2K | 0.02% | 302 |
|
|
2020
Q3 | $327K | Sell |
5,426
-532
| -9% | -$32K | 0.02% | 279 |
|
|
2020
Q2 | $350K | Sell |
5,958
-5,911
| -50% | -$354K | 0.03% | 251 |
|
|
2020
Q1 | $662K | Buy |
+11,869
| New | +$725K | 0.07% | 160 |
|
|
2019
Q2 | – | Sell |
-33,000
| Closed | -$1.57M | – | 261 |
|
|
2019
Q1 | $1.57M | Buy |
+33,000
| New | +$1.64M | 0.13% | 132 |
|
|
2017
Q1 | – | Sell |
-13,747
| Closed | -$803K | – | 84 |
|
|
2016
Q4 | $803K | Sell |
13,747
-3,933
| -22% | -$215K | 0.19% | 35 |
|
|
2016
Q3 | $953K | Buy |
+17,680
| New | +$1.14M | 0.24% | 28 |
|
Other funds holding BMY
Miracle Mile Advisors's BMY Position: Q2 2026 in Review
Miracle Mile Advisors reduced its Bristol-Myers Squibb (BMY) stake by 0.23% in Q2 2026, selling an estimated $14.8K and leaving 111,561 shares worth $6.43M. The position accounts for 0.08% of the portfolio, ranked #181.
Miracle Mile Advisors first reported a position in BMY in Q3 2016 and has held it in 29 quarters since. The position peaked at $6.86M in Q1 2025. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Miracle Mile Advisors held 111,561 shares of Bristol-Myers Squibb worth $6.43M as of Q2 2026.
- Miracle Mile Advisors sold 257 Bristol-Myers Squibb shares in Q2 2026, an estimated $14.8K.
- Bristol-Myers Squibb made up 0.08% of Miracle Mile Advisors's portfolio in Q2 2026, its #181 holding.
- Miracle Mile Advisors first reported a position in Bristol-Myers Squibb in Q3 2016 and has held it in 29 quarters since.
- Miracle Mile Advisors's Bristol-Myers Squibb position peaked at $6.86M in Q1 2025.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Miracle Mile Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.